item management s discussion and analysis of financial condition and results of operations results of operations in connection with the safe harbor provisions of the private securities litigation reform act of  the company provides the following cautionary remarks regarding important factors which  among others  could cause future results to differ materially from the forward looking statements  expectations and assumptions expressed or implied herein 
the following discussion includes certain forward looking statements 
such forward looking statements are subject to a number of factors  including material risks and uncertainties  including those referred to herein and in the company s reports on form q  which could cause actual results to differ materially from the forward looking statements 
year ended december  versus december  net sales decreased million  or for the twelve months ended december  as compared to the same period for the decrease is due primarily to decreases in sales of transdermal nitroglycerin patches and synthetic fabrics of million and million  respectively 
sales of transdermal nitroglycerin patches  manufactured and marketed by hercon laboratories decreased due primarily to the absence of sales to a former domestic distributor and current competitor of the company who accounted for approximately of the company s sales for the year ended december  sales to both of the company s current domestic distributors of nitroglycerin patches also decreased during as compared to during the first half of  in anticipation of increased market pressures and delays in approvals from the united states food and drug administration fda for the sale of new nitroglycerin patches  the company undertook an organizational restructuring which is expected to reduce annual payroll related expenses by approximately  while the company hopes to receive approvals for its new nitroglycerin patches in  no assurances can be made that any new nitroglycerin patches will be approved by the fda 
moreover  the company s ability to exploit its new nitroglycerin products may be limited in the absence of a favorable resolution to its litigation with key 
see note of the notes to consolidated financial statements and discussion below 
the synthetic fabrics sales decrease is due primarily to lower sales of industrial fabrics  eliminating unprofitable business including certain government contracts and lower demand from certain customers 
gross profit decreased million  or  for the twelve months ended december  as compared to the same period in gross profit as a percent of sales was for the twelve months ended december  and for the same period in gross profit for transdermal nitroglycerin patches and synthetic fabrics decreased million and  respectively  while environmental products gross profit increased  as compared to the same period in plant overhead decreased million  including a 
million decrease for payroll related expenses  for the twelve months ended december  as compared to the same period in reflecting  in part  the organizational restructuring and cost reduction program 
transdermal nitroglycerin patch gross profit decreased due primarily to decreased domestic sales volumes of higher margin products 
transdermal nitroglycerin patch plant overhead decreased  including a  decrease for payroll related expenses  for the year ended december  as compared to the same period in reflecting  in part  the organizational restructuring 
the synthetic fabrics gross profit decrease is due primarily to lower gross profit of  at pacific combining partially offset by higher gross profit of  at herculite 
herculite s gross profit increased  despite lower sales volumes of million due primarily to utilizing the computerized inventory management system to improve the manufacturing process and implement cost reduction efforts and by identifying and eliminating unprofitable business including certain government contracts 
in  management will continue to apply manufacturing methods and cost reduction techniques proven at herculite  to pacific in efforts to improve gross profit results 
plant overhead for synthetic fabrics decreased  including a  decrease for payroll related expenses  for the twelve months ended december  as compared to the same period in reflecting  in part  the organizational restructuring and cost reduction program 
environmental products gross profit increased  due primarily to decreased plant overhead expenses along with improved product mix 
selling  general and administrative expenses decreased 
million for the twelve months ended december  as compared to the corresponding period in the decrease is due primarily to lower payroll related expenses of 
million and 
million for consulting service expenses related to the company s applications with the fda to market improved transdermal nitroglycerin products 
legal expenses decreased million for the twelve months ended december  as compared to the same period in the decreased legal expenses are due primarily to reduced activity associated with the defense of the action brought by key against hercon laboratories see note of the notes to consolidated financial statements 
research and development expense decreased 
million for the twelve months ended december  as compared to the same period in payroll related expenses decreased 
million reflecting the organizational restructuring while outside testing and clinical material expenses increased 
million 
all other increases and decreases were not individually significant 
the company expects total research and development expenses related to pharmaceutical products in to be lower than levels 
net interest expense increased 
million for the twelve months ended december  as compared to the same period in due primarily to higher average outstanding balances on borrowings 
other income net decreased  for the twelve months ended december  as compared to the same period in the decrease is due primarily to nonrecurring proceeds received in the third quarter of related to the settlement of a lawsuit 
loss from operations before taxes and minority interest increased million for the twelve month period ended december  as compared to the corresponding period in due primarily to the loss of sales and gross profits for transdermal nitroglycerin patches partially offset by a decrease in legal expenses related to the key litigation 
the company reported a million tax benefit on a million loss from operations for the twelve months ended december  as compared to a 
million tax benefit on a million loss from operations in income tax provision or benefit varies with the amount and nature of the components of income or loss from operations before income taxes 
in  the company recorded a valuation allowance of  against current year tax assets 
in  a tax benefit was increased by adjustments to reserves for a settlement with a local taxing authority of disputed tax assessments pertaining to prior years of  and a reversal of a portion of the valuation allowance amounting to  note to the accompanying consolidated financial statements presents a reconciliation of taxes on income for and minority interest represents a interest of a former hercon laboratories president in the equity of hercon environmental 
year ended december  versus december  net sales increased million  or for the twelve months ended december  as compared to the same period for the increase was due primarily to increases in sales of synthetic fabrics and environmental products of 
million and 
million  respectively  partially offset by a 
million decrease in sales of the company s transdermal nitroglycerin patches 
the synthetic fabrics sales increase was due principally to higher industrial fabrics sales which includes increased governmental and agricultural sales 
environmental products sales increased due primarily to several new insect mating disruptant products introduced in early sales of transdermal nitroglycerin patches manufactured and marketed by hercon laboratories decreased due primarily to lower sales to a former domestic distributor of the company  which obtained approval from the fda for the manufacture and sale of its own nitroglycerin patches in august this former distributor  which currently competes with the company in the nitroglycerin patch market  accounted for approximately and of the company s sales for the years ended december  and december   respectively 
sales to all of the company s other domestic distributors of nitroglycerin patches increased for the twelve months ended december  as compared to the same period in gross profit increased 
million  or  for the twelve months ended december  as compared to the same period in gross profit as a percent of sales was for both of the twelve month periods ended december  and gross profit for synthetic fabrics increased 
million while transdermal nitroglycerin patch gross profit decreased 
million as compared to the same period in the synthetic fabrics gross profit increase was primarily a result of greater sales volumes  improved manufacturing variances and lower raw material costs 
reducing manufacturing variances and lowering raw material costs were the primary focus of cost reduction efforts in transdermal nitroglycerin patch gross profit decreased due primarily to decreased domestic and foreign sales volumes of higher margin products 
gross profit as a percent of sales for transdermal nitroglycerin patches was for the twelve months ended december  as compared to for the same period in reflecting decreased domestic sales volumes offset partially by domestic price increases and reduced operating costs 
selling  general and administrative expenses increased 
million for the twelve months ended december  as compared to the corresponding period in the increase was due primarily to higher payroll related expenses of 
million  including 
million related to pension accruals  and 
million for consulting costs primarily related to the company s efforts of obtaining approval from the fda for its new nitroglycerin patches 
these and other increases were partially offset by decreased sales commissions and royalty expense 
legal expenses increased million for the twelve months ended december  as compared to the same period in in august  key commenced an action against hercon laboratories relating to some of hercon laboratories improved transdermal nitroglycerin products 
the increased legal expenses were primarily due to the costs related to the defense of this action  including preparing for and conducting a two week trial which was completed on october  see note of the notes to consolidated financial statements 
research and development expense decreased 
million for the twelve months ended december  lower outside testing and clinical material expenses related to pharmaceutical products research  along with lower product development costs related to synthetic fabrics research contributed to the decrease 
net interest expense decreased 
million for the twelve months ended december  as compared to the same periods in due primarily to capitalized interest related to new equipment under construction 
other income net decreased  for the twelve months ended december  as compared to the same period in the decrease was due primarily to non recurring income producing items 
loss from operations before taxes and minority interest increased million for the twelve month period ended december  as compared to the corresponding period in due primarily to the increase in legal expenses related to the litigation described above 
the company reported a 
million tax benefit on a million loss from operations for the twelve months ended december  as compared to less than a 
million tax benefit on a 
million loss from operations in in  a tax benefit was increased by adjustments to reserves for a settlement with a local taxing authority of disputed tax assessments pertaining to prior years of  and a reversal of a portion of the valuation allowance amounting to  in  the federal tax benefit resulting from this loss was partially offset by the provision for state taxes which was generated from income associated with the sale of transdermal nitroglycerin patches 
liquidity and capital resources the following measures of liquidity are drawn from the company s consolidated financial statements december  working capital current assets less current liabilities  in thousands   current ratio current assets current liabilities quick ratio cash and receivables current liabilities 

working capital decreased million from december  to december  due to a million decrease in current assets partially offset by a 
million decrease in current liabilities 
accounts receivable and accounts payable decreased million and 
million  respectively  while accrued expenses and other current liabilities increased 
million 
the accounts receivable decrease reflects lower sales volumes for transdermal nitroglycerin patches and synthetic fabrics 
the accounts payable decrease reflects lower expenses related to cost reduction efforts and a reduction in amounts payable to raw material vendors 
accrued expenses and other current liabilities increased 
million due primarily to a 
million increase in the current portion of long term debt see note of the notes to consolidated financial statements 
deferred taxes current and income taxes payable federal were reclassified to deferred taxes non current 
cash used for operations for the twelve months ended december  was million as compared to cash provided by operations of million for the same period in the decrease is due primarily to increasing inventories of 
million and decreasing accounts payable of 
million in as compared to decreasing inventories of million and increasing accounts payable of million in investing activities for the twelve months ended december  provided cash of 
million as compared to the same period in which used cash of million 
this increase is due primarily to lower additions to property  plant and equipment for which reflects the completion of the new production line for pacific in early financing activities for the twelve months ended december  provided million of cash as compared to the same period in which consumed million of cash 
in  financing activities provided cash for operations  compared to when cash from operations was used by financing activities to reduce outstanding debt 
the company has not paid cash dividends and does not anticipate paying such dividends on its common stock in the foreseeable future 
on january   the company replaced a  line of credit and a  term loan from the first national bank of maryland first national with secured financing from ibj schroder business credit corporation formerly ibj schroder bank trust company ibjs 
pursuant to a revolving credit term loan and security agreement loan agreement dated as of january   the company was provided with up to  in term loans and up to  in revolving credit 
proceeds from borrowings under the loan agreement were used by the company to repay outstanding indebtedness under the aggregate  facility with first national 
the term loans were intended to be used to repurchase  repay and or redeem up to  of the company s convertible subordinated debentures due april   as market conditions warrant 
term loan advances were limited to  until the resolution of the litigation between hercon laboratories and key in such a way as to be immaterial on the future operations of the company 
borrowings under the ibjs facility are collateralized by a pledge of substantially all of the assets of the company 
the loan agreement  which expires on january   was subject to various covenants which  among other things  required the company to maintain specified ratios of net worth  current ratio  fixed charge coverage  minimum level of earnings before taxes  depreciation and amortization and limits capital expenditures 
on january   the company entered into a first amendment amendment to the loan agreement with ibjs 
the amendment  among other things  amends the terms for drawing upon the term loan and amends certain financial covenants effective with the december  covenants 
at december   the company was in compliance with the covenants  as amended 
pursuant to the amendment  the maximum term loan amount was reduced to  from  providing an aggregate of up to  in senior secured financing 
the interest rates on the revolving credit line and term loans increased to ibjs s prime plus 
and ibjs s prime plus  respectively 
these rates are subject to a 
decrease upon ibjs s satisfactory review of the financial statements for the year ended december  the company pays a facility fee of of on the amount of the unused available financing facility 
at december  the company had borrowed million on its revolving line of credit from ibjs and million in term loans 
a million term loan increase in the second quarter of was used to purchase the company s convertible subordinated debentures to meet the april sinking fund requirements 
the  revolving credit line borrowing base is limited to the sum of of eligible accounts receivable and of eligible inventory 
the eligible amount is evaluated monthly 
for the twelve months ended december   the maximum eligible amount of the  revolving credit line  has ranged from  to  or from to 
the company expects to meet 
million of debenture interest payments on its convertible subordinated debentures each april and october and other periodic interest payments out of working capital 
the required million sinking fund payment on the company s subordinated debentures due on april  was satisfied by application of 
million debentures previously repurchased and by the company s redemption of an additional million of debentures 
in market transactions throughout the twelve months of  the company purchased 
million principal amount of its subordinated debentures for 
million 
additional debentures may be repurchased and retired or if debentures are not available for purchase  the company has an option to call for redemption the amount required to meet sinking fund requirements 
the company has elected to satisfy the sinking fund requirement by application of 
million of debentures previously repurchased or redeemed  of which 
million were purchased in  and by calling for redemption of the remaining million 
the company intends to fund this redemption of million in april through a term loan pursuant to the loan agreement  subject to ibjs s satisfactory review of the financial statements for the month ended march   including compliance with all financial covenants 
the company expects to be in compliance with all financial covenants at march the company s debt to equity ratio increased to at december  and was at december  the company s debt to equity ratio increased at december  reflecting a million net loss for the twelve months ended 
management believes anticipated expenditures in such as capital expenditures  research and development costs and other operating expenses will be financed by cash generated from operations and the utilization of the company s credit facility from ibjs 
the term loan portion of up to  of the overall  credit facility from ibjs will be used for the repurchasing of debentures 
the company anticipates capital expenditures for property  plant and equipment in not to exceed million 
these capital expenditures will primarily consist of manufacturing equipment 
at december  the company had expended  for capital expenditures for property  plan and equipment in inflation the company believes that inflation has not had a material effect upon its results of operations and liquidity and capital resources for any of the periods presented 
impact of the year issue the year issue is the result of computer programs being written using two digits rather than four to define the applicable year 
any of the company s computer programs that have date sensitive software may recognize a date using as the year rather than the year this could result in a system failure or miscalculations causing disruptions of operations  including  among other things  a temporary inability to process transactions  send invoices  or engage in similar normal business activities 
based on a recent assessment  the company determined that it will be required to modify or replace significant portions of its software so that its computer systems will properly utilize dates beyond december  the company presently believes that with modifications to existing software and conversions to new software  the year issue can be resolved 
however  if such modifications and conversions are not made  or are not completed on a timely basis  the year issue could have a material impact on the operations of the company 
the company will utilize both internal and external resources to reprogram or replace  and test the software for year modifications 
the company plans to complete the year project no later than june  the total cost of the year project is estimated at  and is being funded through operating cash flows 
the total project cost will be expensed as incurred over the next two years and is not expected to have a material effect on the results of operations 
to date  the company has not incurred any external costs related to the assessment of  and preliminary efforts in connection with  its year project and the development of a remediation plan 
the costs of the project and the date on which the company plans to complete the year modifications are based on management s best estimates  which were derived utilizing numerous assumptions of future events including the continued availability of certain resources and other factors 
however  there can be no guarantee that these estimates will be achieved and actual results could differ materially from those plans 
specific factors that might cause such material differences include  but are not limited to  the availability and cost of personnel trained in this area  the ability to locate and correct all relevant computer codes  and similar uncertainties 
implementation of new financial accounting standards in june  the financial accounting standards board fasb issued statement of financial accounting standards no 
reporting comprehensive income sfas 
sfas establishes standards for reporting and display of comprehensive income and its components revenues  expenses  gains and losses in a full set of general purpose financial statements 
sfas no 
requires that an enterprise a classify items of other comprehensive income by their nature in a financial statement and b display the accumulated balance of other comprehensive income separately from retained earnings and additional paid in capital in the equity section of a statement of financial position 
sfas is effective for financial statements issued for periods beginning after december  the company does not expect the implementation of sfas to have a material impact on the consolidated financial statements of the company 
in june  the fasb issued statement of financial accounting standards no 
disclosures about segments of an enterprise and related information sfas 
sfas establishes standards for the way that public business enterprises report information about operating segments in annual financial statements and requires that those enterprises report selected information about operating segments in interim financial reports issued to shareholders 
sfas also establishes standards for related disclosures about products and services  geographic areas and major customers 
sfas is effective for financial statements for periods beginning after december  in the initial year of application  comparative information for earlier years is to be restated 
the company is still evaluating the impact of sfas on segment disclosures 

